Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial

Study Purpose

The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English. The main questions it aims to answer are: Can ketorolac help control pain as effectively or better than opioids after hip arthroscopy? Will ketorolac use reduce the amount of opioid medication needed after surgery? Researchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery. Participants will: Be randomly assigned to one of two groups: The control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam) The experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole) Receive their assigned pain medications after hip arthroscopy.Be asked to: Take the prescribed medications after discharge.Complete a pain journal for 5 days following surgery, documenting pain levels and any side effects.Complete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery.The main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores. The hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective pain relief with fewer risks, and future patients could benefit from improved pain management options.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 89 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients undergoing hip arthroscopy over the age of 18 with Dr.
T. Sean Lynch.
  • - Diagnosis of femoroacetabular impingement (FAI)

    Exclusion Criteria:

    - Patients with inability to consent and/or do not speak English.
  • - Patients with conditions contraindicated with NSAIDs (medication allergy, peptic ulcer disease, bleeding diathesis, and renal disease) - Patients with history of drug and alcohol use disorder.
  • - Patients with chronic analgesia (filled two opioid prescriptions within 6 months of the surgery) - Patients with psychotropic medication usage.
  • - Patients who take pentoxifylline, probonecid, aspirin, and/or NSAIDs who cannot stop taking it for the study.
- Patients who are not discharged same day after surgery

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT07037888
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 4
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Henry Ford Health System
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Femoracetabular Impingement, Hip Arthroscopy
Arms & Interventions

Arms

Placebo Comparator: Control

The standard of care/control pain protocol

Active Comparator: Ketorolac

Intra-operative IV and Oral doses of Ketorolac plus Standard of care

Interventions

Drug: - Ketorolac

IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0

Drug: - Control (Standard treatment)

hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets

Drug: - Control (Standard treatment)

indomethacin 75mg 1 tablet QD to start on POD0 10 tablets

Drug: - Control (Standard treatment)

diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets

Drug: - Omeprazole

20 mg qd

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Henry Ford Health, Detroit 4990729, Michigan 5001836

Status

Recruiting

Address

Henry Ford Health

Detroit 4990729, Michigan 5001836, 48202

Site Contact

Jhamal Wallace

[email protected]

(800) 436-7936